FDA
-
-
-
-
-
-
-
Rigel Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
-
-
-
-
-
-
-
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
-
-
-
-
-
-
-
Rigel Pharma (RIGL) Appoints Mark W. Frohlich, M.D. to Board of Directors
-
-
-
-
-
-
-
Rigel Provides Business Update and 2025 Outlook
-
-
-
-
-
-
-
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
-
-
-
-
-
-
-
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

